[Click eStock] "Pharmaresearch, Rapid Growth Fueled by Skin Booster 'Rejuran'"

Kiwoom Securities has set the target price for Pharmariseoch, a regenerative medicine specialist company, at 230,000 KRW. It is expected that the domestic and international sales of the skin regeneration medical device (skin booster) 'Rejuran' will continue to increase.

Photo caption: The Rejuran® Healer Turnover Ampoule, which manages the skin regeneration cycle, sold out completely during the exclusive launch broadcast on GS Home Shopping.

Minsoo Shin, an analyst at Kiwoom Securities, said, "The popularity of the skin booster Rejuran will continue," and forecasted, "In the third quarter of this year, sales and operating profit are expected to increase by 30.9% and 17.7% year-on-year, reaching 90.1 billion KRW and 32.4 billion KRW, respectively."

Analyst Shin added, "In Korea, the expansion of procedures among Koreans and the steady influx of foreign tourists will lead to rapid growth in sales of the medical device division," and "exports are also increasing to major Asian countries such as China, Singapore, Thailand, and Japan."

He predicted, "Pharmaceutical products, including cosmetics and toxins that share the Rejuran brand, will continue to show increasing sales trends as the export regions diversify."